Madrigal Pharmaceuticals, Inc. Stock News

Morgan Stanley lessened its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 64.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,677 shares of the biopharmaceutical companys stock after selling 169,221 shares during the quarter. Morgan Stanley owned about 0.56% []

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fa

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatt

JMP Securities restated their buy rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a report published on Wednesday, Price Targets.com reports. JMP Securities currently has a $219.00 price target on the biopharmaceutical companys stock. Several other brokerages have also commented on MDGL. Evercore ISI began coverage on Madrigal Pharmaceuticals in a research report on Sunday, []

Price T Rowe Associates Inc. MD trimmed its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 10.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,255 shares of the biopharmaceutical companys stock after selling 9,286 shares during the quarter. Price []

Man Group plc increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 32.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 18,700 shares of the biopharmaceutical companys stock after acquiring an additional 4,600 shares during the period. Man Group plc owned about 0.11% of Madrigal []

Madrigal announced data at AASLD that was published earlier. They have their most important catalyst coming up.

In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH In recognition of Liver Awareness Month, Madrigal and Fatty Li

CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplish

CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension stu

CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NA